These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
169 related articles for article (PubMed ID: 10916970)
21. Insurance coverage for prescription drugs: effects on use and expenditures in the Medicare population. Lillard LA; Rogowski J; Kington R Med Care; 1999 Sep; 37(9):926-36. PubMed ID: 10493470 [TBL] [Abstract][Full Text] [Related]
22. Medicare part D prescription drug benefit--part 1 of 2. Klein CA Nurse Pract; 2006 Feb; 31(2):61. PubMed ID: 16452904 [No Abstract] [Full Text] [Related]
23. Marketplace. Managed care plans try to cope as drug ads spur patient demand. Moskowitz DB Med Health; 1998 May; 52(20):suppl 1-2. PubMed ID: 10179010 [No Abstract] [Full Text] [Related]
24. The prescription-drug problem. Steinbrook R N Engl J Med; 2002 Mar; 346(11):790. PubMed ID: 11893789 [No Abstract] [Full Text] [Related]
25. Trends and determinants of prescription drug expenditures in the elderly: data from the British Columbia Pharmacare Program. Anderson GM; Kerluke KJ; Pulcins IR; Hertzman C; Barer ML Inquiry; 1993; 30(2):199-207. PubMed ID: 8314608 [TBL] [Abstract][Full Text] [Related]
26. Perverse incentives in the Medicare prescription drug benefit. McAdams D; Schwarz M Inquiry; 2007; 44(2):157-66. PubMed ID: 17850042 [TBL] [Abstract][Full Text] [Related]
27. Predictability of prescription drug expenditures for Medicare beneficiaries. Wrobel MV; Doshi J; Stuart BC; Briesacher B Health Care Financ Rev; 2003; 25(2):37-46. PubMed ID: 15124376 [TBL] [Abstract][Full Text] [Related]
28. Using time-series intervention analysis to understand U.S. Medicaid expenditures on antidepressant agents. Ferrand Y; Kelton CM; Guo JJ; Levy MS; Yu Y Res Social Adm Pharm; 2011 Mar; 7(1):64-80. PubMed ID: 21397882 [TBL] [Abstract][Full Text] [Related]
29. Patients who pay out-of-pocket receive lower-cost drugs. Am J Health Syst Pharm; 1998 Aug; 55(15):1556-8. PubMed ID: 9706178 [No Abstract] [Full Text] [Related]
30. Pharmaceutical insurance and the demand for prescription pharmaceuticals in Västerbotten, Sweden. Rudholm N Scand J Public Health; 2005; 33(1):50-6. PubMed ID: 15764241 [TBL] [Abstract][Full Text] [Related]
32. Prescription drug benefits: cost management issues for Medicare. Fox PD Health Care Financ Rev; 2003; 25(2):7-21. PubMed ID: 15124374 [TBL] [Abstract][Full Text] [Related]
33. Medicare drugs. Poisal JA Health Care Financ Rev; 2003; 25(2):1-5. PubMed ID: 15124373 [TBL] [Abstract][Full Text] [Related]
34. Medicaid prescription drug coverage: state efforts to control costs. Gencarelli DM NHPF Issue Brief; 2003 May; (790):1-17. PubMed ID: 12751504 [TBL] [Abstract][Full Text] [Related]
35. The Effect of Medicare Part D on Pharmaceutical Prices and Utilization. Duggan M; Morton FS Am Econ Rev; 2010 Mar; 100(1):590-607. PubMed ID: 29508975 [No Abstract] [Full Text] [Related]
36. Medicare coverage of prescription drugs. Division of Advocacy and Health Policy Bull Am Coll Surg; 2005 Sep; 90(9):29-30, 62. PubMed ID: 18435099 [No Abstract] [Full Text] [Related]
38. Drug coverage for Medicare beneficiaries: why protection may be in jeopardy. Briesacher B; Stuart B; Shea D Issue Brief (Commonw Fund); 2002 Jan; (505):1-8. PubMed ID: 11922051 [No Abstract] [Full Text] [Related]
39. Part I--Medicare prescription drug coverage (Part D): the promise. Witten B Nephrol News Issues; 2006 Jul; 20(8):14, 17-8. PubMed ID: 16859229 [No Abstract] [Full Text] [Related]
40. What's the benefit? A new federal Medicare drug plan stimulates independent actions and new ideas, but what's the future role for states? Cauchi R State Legis; 2004; 30(7):28-33. PubMed ID: 15241878 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]